Literature DB >> 31468168

[Experiences and results from Rheuma-VOR].

A Schwarting1,2, M Dreher3, G Assmann4, T Witte5, K Hoeper5,6, R E Schmidt5.   

Abstract

Rheumatoid arthritis, psoriatic arthritis and axial spondylarthritis are the most common chronic autoimmune rheumatic diseases. For all three diseases an early diagnosis and initiation of treatment is crucial. The proof of concept network study "Rheuma-VOR" is a further developed version of the predecessor project ADAPTHERA and was extended to several federal states. The aim of this prospective study is to improve the early diagnosis of rheumatoid arthritis, psoriatic arthritis and axial spondylarthritis and thus positively impact the quality of care for patients with the help of multidisciplinary coordinating centers. To date 3710 disease-specific questionnaires from patients with the suspected diagnosis of rheumatoid arthritis, psoriatic arthritis or axial spondylarthritis from 1298 different primary care providers were registered in the multidisciplinary coordination centers. A total of 1958 appointments were made with 1 of the 53 participating rheumatology specialists. In 876 patients, 1 of the 3 rheumatic diseases was diagnosed in an early stage. The waiting period was on average 42.5 days depending on the federal state, which is well below the nationwide average. It should also be noted that the coordinated cooperation and risk stratification of the Rheuma-VOR coordination centers relieved the capacity of rheumatology specialists by 1281 appointments (34.5%). In addition, the 2‑week Rheuma Bus Tour and the accompanying initiatives in Rhineland-Palatinate (Rheuma-VOR screening app and the triage consultation) are showing first promising positive results.

Entities:  

Keywords:  Axial spondylarthritis; Early recognition; Health services research; Psoriatic arthritis; Rheumatoid arthritis

Mesh:

Year:  2019        PMID: 31468168     DOI: 10.1007/s00393-019-00694-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  15 in total

1.  Long-term impact of delay in assessment of patients with early arthritis.

Authors:  Michael P M van der Linden; Saskia le Cessie; Karim Raza; Diane van der Woude; Rachel Knevel; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2010-12

2.  [The regional network ADAPTHERA : Rheumatology care through coordinated cooperation: comprehensive, trans-sectoral, covering all health insurance. Initial results].

Authors:  A Schwarting; B Pfeiff; C Amberger; D Pick; M Hesse; M Jendro; J Engels; A Böttger; C Kuhn; J Majdandzic; W Ziese; M-L Stadelmann; F W Kessler; H Dinges; S Ultes-Kaiser; U Droste; M Schmalhofer; A Hazenbiller; M Rector; J Weinmann-Menke; K Triantafyllias; M Becker; M Ataian; M Lablans; F Ueckert; T Panholzer; M Blettner
Journal:  Z Rheumatol       Date:  2016-12       Impact factor: 1.372

3.  [How frequent are musculoskeletal diseases in Germany?].

Authors:  A Zink; K Albrecht
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

4.  [Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016].

Authors:  A Zink; J Braun; E Gromnica-Ihle; D Krause; H J Lakomek; W Mau; U Müller-Ladner; J Rautenstrauch; C Specker; M Schneider
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

Review 5.  Epidemiology of spondyloarthritis: a review.

Authors:  Gunnstein Bakland; Hans C Nossent
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

6.  [ADAPTHERA-Statewide cross-sectoral care network for patients with early rheumatoid arthritis shows sustained remission in standard care].

Authors:  A Lauter; K Triantafyllias; R Leiß; C Amberger; J Engels; M Hesse; M Jendro; J Gilly; M-L Stadelmann; W Ziese; D Wollschläger; M Dreher; B Pfeiff; J Weinmann-Menke; T Panholzer; A Schwarting
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

7.  [Diagnostic spectrum, treatment indication and symptom duration in initial referrals to the rheumatologist].

Authors:  G Westhoff; E Edelmann; J Kekow; A Zink
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

8.  [Healthcare research in rheumatology. Current state].

Authors:  A Zink
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

9.  [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].

Authors:  K Albrecht; D Huscher; T Eidner; S Kleinert; S Späthling-Mestekemper; S Bischoff; A Zink
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

Review 10.  A systematic review of web-based interventions for patient empowerment and physical activity in chronic diseases: relevance for cancer survivors.

Authors:  Wilma Kuijpers; Wim G Groen; Neil K Aaronson; Wim H van Harten
Journal:  J Med Internet Res       Date:  2013-02-20       Impact factor: 5.428

View more
  4 in total

Review 1.  [Physical activity, exercise and nutrition in rheumatism : Adjuvant treatment options for inflammatory-rheumatic diseases].

Authors:  M Dreher; M Kosz; A Schwarting
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

Review 2.  [Digital diagnostic support in rheumatology].

Authors:  J Knitza; M Krusche; J Leipe
Journal:  Z Rheumatol       Date:  2021-10-04       Impact factor: 1.372

3.  Toward Earlier Diagnosis Using Combined eHealth Tools in Rheumatology: The Joint Pain Assessment Scoring Tool (JPAST) Project.

Authors:  Johannes Knitza; Rachel Knevel; Karim Raza; Tor Bruce; Ekaterina Eimer; Isabel Gehring; Linda Mathsson-Alm; Maryam Poorafshar; Axel J Hueber; Georg Schett; Martina Johannesson; Anca Catrina; Lars Klareskog
Journal:  JMIR Mhealth Uhealth       Date:  2020-05-15       Impact factor: 4.773

Review 4.  [Perspectives for rheumatological health services research at the German Rheumatism Research Center].

Authors:  K Albrecht; F Milatz; J Callhoff; I Redeker; K Minden; A Strangfeld; A Regierer
Journal:  Z Rheumatol       Date:  2020-12-01       Impact factor: 1.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.